Investment Thesis
Coherus Oncology is a pre-commercial or early-stage biotech company burning significant cash ($57.9M operating, $58.2M free cash flow) with minimal revenue generation ($12.3M) and no path to profitability visible. While 59.8% revenue growth and a $115.2M cash position provide near-term runway (~2 years), the company faces severe unit economics with negative operating margins (-293.7%) that require fundamental business model improvement or successful product commercialization to avoid dilutive financing.
Strengths
- Strong absolute cash position of $115.2M provides operational runway
- Revenue growth of 59.8% YoY demonstrates some market traction and commercial progress
- Reasonable short-term liquidity (1.56x current ratio, 1.52x quick ratio) and moderate leverage (0.94x debt-to-equity)
Risks
- Severe cash burn of $57.9M annually with negative FCF limits runway to approximately 2 years at current burn rate
- Operating losses of $36.2M and net losses of $38.3M indicate company cannot support expenses from revenue; no profitability visibility
- Data quality concerns (942.7% gross margin with $12.3M revenue generating $116.1M gross profit) suggest potential accounting or reporting issues that undermine financial statement reliability
- Negative interest coverage (-16.5x) and significant debt ($73.7M) create refinancing risk if cash depletes
Key Metrics to Watch
- Quarterly revenue growth trajectory and whether 59.8% growth rate accelerates or decelerates
- Operating cash flow burn rate and runway extension through cost controls or revenue inflection
- Achievement of clinical/commercialization milestones that could improve unit economics and reduce cash burn
Financial Metrics
Revenue
12.3M
Net Income
-38.3M
EPS (Diluted)
$-0.28
Free Cash Flow
-58.2M
Total Assets
266.0M
Cash
115.2M
Profitability Ratios
Gross Margin
942.7%
Operating Margin
-293.7%
Net Margin
-311.3%
ROE
-48.7%
ROA
-14.4%
FCF Margin
-472.6%
Balance Sheet & Liquidity
Current Ratio
1.56x
Quick Ratio
1.52x
Debt/Equity
0.94x
Debt/Assets
70.4%
Interest Coverage
-16.54x
Long-term Debt
73.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:06:54.939572 |
Data as of: 2026-03-31 |
Powered by Claude AI